NCT02701582

Brief Summary

This is a prospective, randomized controlled trial to determine if using FloTrac/EV1000 system in neurosurgical patients undergoing craniotomies for aneurysm repair or tumor resection complicated by cerebral edema, or complex spinal surgery including multi-level scoliosis correction, is a more effective way of monitoring fluid.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 22, 2016

Completed
15 days until next milestone

First Posted

Study publicly available on registry

March 8, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
3 years until next milestone

Results Posted

Study results publicly available

August 19, 2019

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

1.8 years

First QC Date

February 22, 2016

Results QC Date

August 9, 2017

Last Update Submit

August 16, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of ICU Stays Greater Than 1.5 Days

    the sum of ICU stays greater than the 1.5 Days eligibility for discharge from hospital according to the surgeon, over the course of 20 Days

    20 Days

Secondary Outcomes (1)

  • Creatinine Change

    Baseline and 72 hours

Other Outcomes (7)

  • Pulmonary Status as Measured by the Number of Participants Who Require Supplemental Oxygen

    1 day

  • Organ Oxygenation as Measured by Serum Lactate

    Baseline and 24 Hours

  • Organ Oxygenation as Measured by Arterial Blood Gas Values

    Baseline and 1 day

  • +4 more other outcomes

Study Arms (2)

Goal Directed Therapy

EXPERIMENTAL

Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.

Drug: PhenylephrineDrug: EpinephrineOther: AlbuminOther: VoluvenOther: Normal SalineOther: Packed Red Blood CellsDevice: FloTrac Monitor

Control Group

ACTIVE COMPARATOR

FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.

Drug: PhenylephrineDrug: EpinephrineOther: AlbuminOther: VoluvenOther: Normal SalineOther: Packed Red Blood CellsDevice: FloTrac Monitor

Interventions

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered

Also known as: Sudafed, Neo-Synephrine, SudoGest
Control GroupGoal Directed Therapy

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered

Also known as: EpiPen, Adrenaclick, Medihaler-Epi
Control GroupGoal Directed Therapy
AlbuminOTHER

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.

Control GroupGoal Directed Therapy
VoluvenOTHER

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.

Control GroupGoal Directed Therapy

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.

Control GroupGoal Directed Therapy

if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.

Control GroupGoal Directed Therapy

FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.

Control GroupGoal Directed Therapy

Eligibility Criteria

Age15 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Neurosurgical patients with concerns for decreased intracranial compliance;
  • Orthopedic spine patients;
  • Patients scheduled to undergo neurosurgical interventions that include any of the following will be eligible: intracranial aneurysm repair; or, major spine surgery.

You may not qualify if:

  • Patients with permanent cardiac arrhythmias;
  • Patients with severe aortic regurgitation;
  • Patients with intra-aortic balloon pump (IABP);
  • Patients undergoing emergency surgery; and,
  • Women who are pregnant and/or nursing will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Intracranial AneurysmBrain EdemaScoliosis

Interventions

PhenylephrinePseudoephedrineAcetaminophenEpinephrineAlbuminsHES 130-0.4Saline Solution

Condition Hierarchy (Ancestors)

Intracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesAneurysmVascular DiseasesCardiovascular DiseasesSpinal CurvaturesSpinal DiseasesBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesPropanolaminesPropanolsPhenethylaminesEthylaminesAcetanilidesAnilidesAmidesAniline CompoundsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsProteinsAmino Acids, Peptides, and ProteinsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Marc Bloom, MD, PHD
Organization
NYU School of Medicine

Study Officials

  • Marc Bloom, MD

    New York University Medical School

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2016

First Posted

March 8, 2016

Study Start

March 1, 2014

Primary Completion

January 1, 2016

Study Completion

September 1, 2016

Last Updated

August 28, 2019

Results First Posted

August 19, 2019

Record last verified: 2019-08

Locations